Tags

Type your tag names separated by a space and hit enter

Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study.
BMC Res Notes 2015; 8:260BR

Abstract

BACKGROUND

Chronic hepatitis C (CHC) is a global health challenge. New therapeutic agents with excellent sustained virological response (SVR) rates are available mainly in developed countries, while the majority of CHC patients live in countries with low health budget. Predictors of therapeutic response are therefore necessary. Vitamin B12 appears to be involved in hepatitis C virus replication.

METHODS

We therefore studied retrospectively the relationship between baseline serum vitamin B12 levels and clinical features in 116 CHC genotype 1 infected patients. Logistic regression models with univariate and multivariate analysis were used in the statistical analysis.

RESULTS

Baseline serum vitamin B12 levels were found to be positively associated with serum transaminase activities (AST, p = 0.002, ALT, p = 0.04), baseline viral load (p < 0.0001), stage of fibrosis (p = 0.0001) and favorable interferon-λ3/4 (IFNL3/IFNL4) rs12979860 genotypes (p = 0.04), and inversely with SVR (p < 0.001) as well as with rapid virological response (p = 0.001). Patients with baseline serum vitamin B12 levels below a cut-off value of 570 ng/L achieved a SVR rate of 59% with an odds ratio (OR) of 13.4 [confidence interval (CI) 4.3-41.9, p < 0.0001] compared to patients above the cut-off value. By combining serum vitamin B12 levels and IFNL3/IFNL4 rs12979860 genotypes, patients with baseline serum vitamin B12 levels below the cut-off value of 570 ng/L and IFNL3/IFNL4 rs12979860 CC genotype achieved a SVR rate of even 80% with an OR of 54 (CI 9.9-293, p < 0.0001) compared to patients above the cut-off value and non-CC-genotypes.

CONCLUSION

Our data suggest baseline serum vitamin B12 levels as useful noninvasive marker for characterizing CHC patients. They might further help to identify responders to a standard treatment.

Authors+Show Affiliations

Department of Gastroenterology and Endocrinology, University Medical Center Goettingen, Georg-August University Goettingen, Robert Koch Strasse 40, 37075, Göttingen, Germany. nicolaecatalin.mechie@med.uni-goettingen.de.Division of Internal Medicine, Clinic of Herzberg and Osterode, Dr Froessel Allee, 37412, Herzberg am Harz, Germany. armin.goralczyk@me.com.Department of Gastroenterology and Endocrinology, University Medical Center Goettingen, Georg-August University Goettingen, Robert Koch Strasse 40, 37075, Göttingen, Germany. lars.reinhardt@med.uni-goettingen.de.Department of Gastroenterology and Endocrinology, University Medical Center Goettingen, Georg-August University Goettingen, Robert Koch Strasse 40, 37075, Göttingen, Germany. smihm@med.uni-goettingen.de.Department of Gastroenterology and Endocrinology, University Medical Center Goettingen, Georg-August University Goettingen, Robert Koch Strasse 40, 37075, Göttingen, Germany. ahmad.amanzada@med.uni-goettingen.de.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26109044

Citation

Mechie, Nicolae-Catalin, et al. "Association of Serum Vitamin B12 Levels With Stage of Liver Fibrosis and Treatment Outcome in Patients With Chronic Hepatitis C Virus Genotype 1 Infection: a Retrospective Study." BMC Research Notes, vol. 8, 2015, p. 260.
Mechie NC, Goralzcyk AD, Reinhardt L, et al. Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study. BMC Res Notes. 2015;8:260.
Mechie, N. C., Goralzcyk, A. D., Reinhardt, L., Mihm, S., & Amanzada, A. (2015). Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study. BMC Research Notes, 8, p. 260. doi:10.1186/s13104-015-1248-z.
Mechie NC, et al. Association of Serum Vitamin B12 Levels With Stage of Liver Fibrosis and Treatment Outcome in Patients With Chronic Hepatitis C Virus Genotype 1 Infection: a Retrospective Study. BMC Res Notes. 2015 Jun 25;8:260. PubMed PMID: 26109044.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study. AU - Mechie,Nicolae-Catalin, AU - Goralzcyk,Armin D, AU - Reinhardt,Lars, AU - Mihm,Sabine, AU - Amanzada,Ahmad, Y1 - 2015/06/25/ PY - 2015/03/26/received PY - 2015/06/17/accepted PY - 2015/6/26/entrez PY - 2015/6/26/pubmed PY - 2016/3/22/medline SP - 260 EP - 260 JF - BMC research notes JO - BMC Res Notes VL - 8 N2 - BACKGROUND: Chronic hepatitis C (CHC) is a global health challenge. New therapeutic agents with excellent sustained virological response (SVR) rates are available mainly in developed countries, while the majority of CHC patients live in countries with low health budget. Predictors of therapeutic response are therefore necessary. Vitamin B12 appears to be involved in hepatitis C virus replication. METHODS: We therefore studied retrospectively the relationship between baseline serum vitamin B12 levels and clinical features in 116 CHC genotype 1 infected patients. Logistic regression models with univariate and multivariate analysis were used in the statistical analysis. RESULTS: Baseline serum vitamin B12 levels were found to be positively associated with serum transaminase activities (AST, p = 0.002, ALT, p = 0.04), baseline viral load (p < 0.0001), stage of fibrosis (p = 0.0001) and favorable interferon-λ3/4 (IFNL3/IFNL4) rs12979860 genotypes (p = 0.04), and inversely with SVR (p < 0.001) as well as with rapid virological response (p = 0.001). Patients with baseline serum vitamin B12 levels below a cut-off value of 570 ng/L achieved a SVR rate of 59% with an odds ratio (OR) of 13.4 [confidence interval (CI) 4.3-41.9, p < 0.0001] compared to patients above the cut-off value. By combining serum vitamin B12 levels and IFNL3/IFNL4 rs12979860 genotypes, patients with baseline serum vitamin B12 levels below the cut-off value of 570 ng/L and IFNL3/IFNL4 rs12979860 CC genotype achieved a SVR rate of even 80% with an OR of 54 (CI 9.9-293, p < 0.0001) compared to patients above the cut-off value and non-CC-genotypes. CONCLUSION: Our data suggest baseline serum vitamin B12 levels as useful noninvasive marker for characterizing CHC patients. They might further help to identify responders to a standard treatment. SN - 1756-0500 UR - https://www.unboundmedicine.com/medline/citation/26109044/full_citation L2 - https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-015-1248-z DB - PRIME DP - Unbound Medicine ER -